Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 Sep 1;75(9):884-893.
doi: 10.1001/jamapsychiatry.2018.1483.

Effect of Repetitive Transcranial Magnetic Stimulation on Treatment-Resistant Major Depression in US Veterans: A Randomized Clinical Trial

Jerome A Yesavage  1   2 , J Kaci Fairchild  1   2 , Zhibao Mi  3 , Kousick Biswas  3 , Anne Davis-Karim  4 , Ciaran S Phibbs  5   6 , Steven D Forman  7   8 , Michael Thase  9 , Leanne M Williams  1   2 , Amit Etkin  1   2   10 , Ruth O'Hara  1   2 , Gerald Georgette  1 , Tamara Beale  1 , Grant D Huang  11 , Art Noda  2 , Mark S George  12   13 ; VA Cooperative Studies Program Study Team
Affiliations
Randomized Controlled Trial

Effect of Repetitive Transcranial Magnetic Stimulation on Treatment-Resistant Major Depression in US Veterans: A Randomized Clinical Trial

Jerome A Yesavage et al. JAMA Psychiatry. .

Abstract

Importance: Treatment-resistant major depression (TRMD) in veterans is a major clinical challenge given the high risk for suicidality in these patients. Repetitive transcranial magnetic stimulation (rTMS) offers the potential for a novel treatment modality for these veterans.

Objective: To determine the efficacy of rTMS in the treatment of TRMD in veterans.

Design, setting, and participants: A double-blind, sham-controlled randomized clinical trial was conducted from September 1, 2012, to December 31, 2016, in 9 Veterans Affairs medical centers. A total of 164 veterans with TRD participated.

Interventions: Participants were randomized to either left prefrontal rTMS treatment (10 Hz, 120% motor threshold, 4000 pulses/session) or to sham (control) rTMS treatment for up to 30 treatment sessions.

Main outcomes and measures: The primary dependent measure of the intention-to-treat analysis was remission rate (Hamilton Rating Scale for Depression score ≤10, indicating that depression is in remission and not a clinically significant burden), and secondary analyses were conducted on other indices of posttraumatic stress disorder, depression, hopelessness, suicidality, and quality of life.

Results: The 164 participants had a mean (SD) age of 55.2 (12.4) years, 132 (80.5%) were men, and 126 (76.8%) were of white race. Of these, 81 were randomized to receive active rTMS and 83 to receive sham. For the primary analysis of remission, there was no significant effect of treatment (odds ratio, 1.16; 95% CI, 0.59-2.26; P = .67). At the end of the acute treatment phase, 33 of 81 (40.7%) of those in the active treatment group achieved remission of depressive symptoms compared with 31 of 83 (37.4%) of those in the sham treatment group. Overall, 64 of 164 (39.0%) of the participants achieved remission.

Conclusions and relevance: A total of 39.0% of the veterans who participated in this trial experienced clinically significant improvement resulting in remission of depressive symptoms; however, there was no evidence of difference in remission rates between the active and sham treatments. These findings may reflect the importance of close clinical surveillance, rigorous monitoring of concomitant medication, and regular interaction with clinic staff in bringing about significant improvement in this treatment-resistant population.

Trial registration: ClinicalTrials.gov Identifier: NCT01191333.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Etkin has equity holdings in Akili Interactive and Mindstrong Health for work unrelated to neurostimulation. No other conflicts were reported.

Figures

Figure 1.
Figure 1.. CONSORT Diagram
rTMS indicates repetitive transcranial magnetic stimulation.
Figure 2.
Figure 2.. Hamilton Rating Scale for Depression Remission Rates Stratified by Presence or Absence of Posttraumatic Stress Disorder (PTSD)
Remission in patients without (A) and with (B) PTSD. Discussion of the effects of PTSD is provided in the Moderators of Treatment Effect section. MDD indicates major depressive disorder.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Hasin DS, Goodwin RD, Stinson FS, Grant BF. Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch Gen Psychiatry. 2005;62(10):1097-1106. doi:10.1001/archpsyc.62.10.1097 - DOI - PubMed
    1. Thase ME. Therapeutic alternatives for difficult-to-treat depression: a narrative review of the state of the evidence. CNS Spectr. 2004;9(11):808-816, 818-821. doi:10.1017/S1092852900002236 - DOI - PubMed
    1. Keller MBLP, Lavori PW, Mueller TI, et al. . Time to recovery, chronicity, and levels of psychopathology in major depression: a 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry. 1992;49(10):809-816. doi:10.1001/archpsyc.1992.01820100053010 - DOI - PubMed
    1. George MS, Taylor JJ, Short EB. The expanding evidence base for rTMS treatment of depression. Curr Opin Psychiatry. 2013;26(1):13-18. doi:10.1097/YCO.0b013e32835ab46d - DOI - PMC - PubMed
    1. Kozel FAGM, George MS, Simpson KN. Decision analysis of the cost-effectiveness of repetitive transcranial magnetic stimulation versus electroconvulsive therapy for treatment of nonpsychotic severe depression. CNS Spectr. 2004;9(6):476-482. - PubMed

Publication types

MeSH terms

Associated data